Bruker Corporation has unveiled the timsMetabo mass spectrometer, designed to significantly enhance sensitivity and specificity in 4D-Metabolomics and 4D-Lipidomics. This breakthrough technology leverages 4D LC-TIMS-MS/MS separations and CCS measurements, offering unparalleled specificity and annotation confidence. A notable feature is the introduction of the 'digital metabolome archive' for AI/ML scaling, supported by the new TIMS Mobility Range Enhancement (MoRE) technology. The QSee™ QC suite, alongside the cloud-based TwinScape™, ensures performance monitoring for reliable metabolomics research. Enhanced TASQ® RealTimeQC capabilities now offer improved data visualization, crucial for intra-batch data quality monitoring. According to Professor Thomas Moritz from the University of Copenhagen, these advancements provide essential quality monitoring, supporting informed decision-making during analysis. Dr. Matthew Lewis of Bruker highlighted the timsMetabo as a transformative innovation in the field, focusing on customer needs and delivering advanced features for data analysis and quality assurance.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。